CORDIS
EU research results

CORDIS

English EN
ANTI-SUPERBUG Precommercial procurement

ANTI-SUPERBUG Precommercial procurement

Objective

Infections caused by resistant microorganisms often fail to respond to the standard treatment, resulting in prolonged hospital stays, higher health care expenditures, and a greater risk of death.1 Antimicrobials Resistant Organism (AMRO) or Superbugs are invisible, and can survive on surfaces for up to three days. That means that they can be transferred when one infected person simply touches another, or when the patient touches something on which the pathogen resides like a stethoscope or a TV remote control.2 Antibiotic resistance varies according to geographic locations and is directly proportional to the use and misuse of antibiotics. Active surveillance systems are in place across all European member states and Norway and are to be considered one of the main contributing factors to the reduction AMRO infections over the years. On the other hand the effort done up to now is not enough to eradicate AMRO/superbugs infections and ANTI-SUPERBUGS PCP will challenge the industry to develop solutions that in contact with resistant microorganisms can detect their presence and give real-time feedback to the user and at the same time share the information with the healthcare provider electronic record systems linking the infection with the place of the detection. The project will be developped with the support of Sara Bedin, who will provide her know-how in Procurement in Innovation.

Coordinator

AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA

Address

Calle Roc Boronat 81 95 2 Piso
08005 Barcelona

Spain

Activity type

Research Organisations

EU Contribution

€ 2 719 657,50

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT CATALA D'ONCOLOGIA

Spain

EU Contribution

€ 131 250

RISE RESEARCH INSTITUTES OF SWEDEN AB

Sweden

EU Contribution

€ 38 937,50

UNIVERSITAETSKLINIKUM AACHEN

Germany

EU Contribution

€ 16 668,75

Sheffield Teaching Hospitals NHS Trust

United Kingdom

EU Contribution

€ 16 668,75

PROVINCIA AUTONOMA DI TRENTO

Italy

EU Contribution

€ 184 380

BEDIN SARA

Italy

EU Contribution

€ 89 250

RISE ACREO AB

Sweden

EU Contribution

€ 38 937,50

HELIOS KLINIKUM WUPPERTAL GMBH

Germany

EU Contribution

€ 166 687,50

FUNDACIO MUTUA DE TERRASSA PER A LA DOCENCIA I RECERCA BIOMEDICA I SOCIAL FUNDACIO PRIVADA CATALANA

Spain

EU Contribution

€ 44 187,50

Project information

Grant agreement ID: 688878

Status

Ongoing project

  • Start date

    1 September 2016

  • End date

    31 August 2021

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 4 923 750

  • EU contribution

    € 3 446 625

Coordinated by:

AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA

Spain